Search
forResearch 10 of 78
- Abiraterone and spironolactone in prostate cancer: a combination to avoid
- Revising the role of the androgen receptor in breast cancer
- Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases
- Redefining hormone resistance in prostate cancer
- Discovery of clinically approved drugs capable of inhibiting SARS-CoV-2 <i>in vitro</i> infection using a phenotypic screening strategy and network-analysis to predict their potential to treat covid-19
- New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics
- Intratumoral <i>De Novo</i> Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors
- HSD3B1 Genotypes Conferring Adrenal-Restrictive and Adrenal-Permissive Phenotypes in Prostate Cancer and Beyond
- Hormone Blocking Anticancer Drugs
- Alopecia With Endocrine Therapies in Patients With Cancer
Learn
— no results
Try a deeper search in learn →Community
— no results
Try a deeper search in community →